Evidence map›Paper›PMID 40752590›Full record

ArticleTransplantation and cellular therapy2025

Outcomes of Patients With Multiple Myeloma With deletion 1p Following Autologous Stem Cell Transplant.

Curtis Marcoux, Denái R Milton, Mark R Tanner, Qaiser Bashir, Samer Srour, Neeraj Saini, Paul Lin, Ashka Patel, Hina N Khan, Jeremy Ramdial and 14 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Transplantation and cellular therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Curtis MarcouxDivision of Hematology, Dalhousie University, Halifax, Canada.
Denái R MiltonDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Mark R TannerDepartment of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Qaiser BashirDepartment of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Samer SrourDepartment of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Neeraj SainiDepartment of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Paul LinDepartment of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Ashka PatelDepartment of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Hina N KhanDepartment of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas; Department of Hematology/Oncology, McGovern Medical School, The University of Texas, Health Sciences Center at Houston, Houston, Texas.
Jeremy RamdialDepartment of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Yago NietoDepartment of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Guilin TangDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Asad HaiderDepartment of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Yosra AljawaiDepartment of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Partow KebriaeiDepartment of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Hans C LeeDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Christine YeDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Krina K PatelDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Sheeba K ThomasDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Robert Z OrlowskiDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Richard E ChamplinDepartment of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Elizabeth J ShpallDepartment of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Muzaffar H QazilbashDepartment of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Oren PasvolskyDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address: opasvolsky@mdanderson.org.

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

backgroundSeveral studies have suggested that a deletion in the short arm of chromosome 1 (del(1p)) is an independent adverse prognostic factor in patients with multiple myeloma (MM). However, its impact on outcomes of patients undergoing autologous hematopoietic cell transplantation (autoHCT) and receiving contemporary anti-myeloma therapy remains unclear. STUDY

designA retrospective, single-center analysis of newly diagnosed MM (NDMM) patients with del(1p) who underwent upfront autoHCT between 2010 and 2021. The primary endpoints were progression-free survival (PFS) and overall survival (OS). Propensity-matched comparisons were performed between del(1p) patients and a control group without del(1p) and with standard-risk cytogenetics.

results55 patients were included in our analysis. With a median follow-up of 24.0 months (range 3.8-79.5), the median PFS was 30.2 months (95% CI 18.0-not reached [NR]) and the median OS was not reached (95% CI 41.1-NR). In multivariable analysis, female patients (hazard ratio [95% CI] 2.81 [1.14, 6.91], P = .025) and those with R2-ISS stage IV (compared with stage II 4.85 [1.01, 23.34], P = .049) had worse PFS, whereas patients who achieved CR as the best post-transplant response had better PFS (0.38 [0.16, 0.91], P = .029). Concomitant del(17p) was associated with a significantly worse OS (4.47 [1.18, 17.02], P = .028). Propensity score matching showed no significant differences in PFS (1.63 [0.86, 3.10], P = .13) or OS (1.77 [0.73, 4.32], P = .21) between del(1p) and control patients.

conclusionsIn NDMM patients undergoing upfront autoHCT, del(1p) alone was not significantly associated with inferior outcomes. However, concurrent del(17p) and del(1p) was associated with worse survival.

Indexed as

Chromosome DeletionChromosomes, Human, Pair 1Hematopoietic Stem Cell TransplantationMultiple MyelomaAdultAgedFemaleHumansMaleMiddle AgedPrognosisRetrospective StudiesTransplantation, AutologousTreatment OutcomeAutologousDeletion 1pMyelomaTransplant

Identifiers

PMID40752590
PMCPMC13423050

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.